# Stem Cell Transplant in Patients With Severe Sickle Cell Disease

> **NCT03421756** · EARLY_PHASE1 · TERMINATED · sponsor: **Kathleen Dorritie** · enrollment: 1 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Alemtuzumab
- **RADIATION:** Total Body Irradiation
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT03421756
- **Lead sponsor:** Kathleen Dorritie
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-29
- **Primary completion:** 2018-09-15
- **Final completion:** 2022-05-15
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Trial terminated due to low rate of enrollment
- **Last updated:** 2022-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03421756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03421756, "Stem Cell Transplant in Patients With Severe Sickle Cell Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03421756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*